KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Treasury Shares (2023 - 2025)

Biocryst Pharmaceuticals' Treasury Shares history spans 5 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 88.97% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 88.97%, while the annual FY2025 figure was $1.0 million, 88.97% down from the prior year.
  • Treasury Shares reached $1.0 million in Q4 2025 per BCRX's latest filing, down from $8.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.3 million in Q4 2024 to a low of $1.0 million in Q4 2025.
  • Average Treasury Shares over 3 years is $6.5 million, with a median of $5.6 million recorded in 2023.
  • The largest YoY upside for Treasury Shares was 73.16% in 2025 against a maximum downside of 88.97% in 2025.
  • A 3-year view of Treasury Shares shows it stood at $5.6 million in 2023, then soared by 66.11% to $9.3 million in 2024, then tumbled by 88.97% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Treasury Shares are $1.0 million (Q4 2025), $8.7 million (Q3 2025), and $8.9 million (Q2 2025).